Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

Quantitative Myocardial Blood Flow and Reserve with Low Dose Rest/High Dose Stress Regadenoson PET/CT-MPI: The Utility of Residual Activity Correction With N-13 Ammonia

Amy Feldkamp, Wendell Yap, Joseph Donald, Bret Press, Amy Dilberto, Michael Feldkamp and Thomas Rosamond
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 24;
Amy Feldkamp
1Cardiovascular Medicine The University of Kansas Health System Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendell Yap
2Nuclear Medicine/Radiology The University of Kansas Health System Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Donald
2Nuclear Medicine/Radiology The University of Kansas Health System Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bret Press
2Nuclear Medicine/Radiology The University of Kansas Health System Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Dilberto
1Cardiovascular Medicine The University of Kansas Health System Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Feldkamp
1Cardiovascular Medicine The University of Kansas Health System Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Rosamond
1Cardiovascular Medicine The University of Kansas Health System Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

24

Objectives: Tracer dose reduction is a desirable societal goal for myocardial perfusion imaging (MPI). Residual activity subtraction methodology may allow for aggressive dose reduction in some instances and is the intent of studies designed to measure its effect on quantification of myocardial blood flow metrics in a variety of compressed dose adjusted protocols. We studied its utility of one such protocol using N13-ammonia. Methods: We studied 150 consecutive patients comparing quantitative myocardial blood flow and flow reserve using a unique low dose resting (6mCi) and high dose stress (16mCi) strategy with regadenoson PET/CT-MPI utilizing N-13 ammonia as the tracer both with and without residual activity subtraction methodology (Cedars QGS:QPS vs. Cedars QGS:QPS Residual Activity Beta Software). A four-ring detector, fully digital, GE Discovery MI PET/CT scanner was employed. All patients confirmed their abstinence of caffeine for a least 12 hours prior to the exam. There was a 10-15-minute delay between the resting and stress acquisitions. Dynamic data sets were acquired in gated list-mode and a 28-frame strategy for 10 minutes both at rest and with stress. CT free-breathing attenuation scans were performed prior to rest and post stress. A 60 second delay was built into the protocol between the completion of the regadenoson infusion and the hand injection of N-13 tracer over 20 seconds, each followed by a 20ml saline flush.

Results: There were 76 female and 74 male patients studied. For the entire group, the global myocardial peak stress blood flow mean was 2.74 ml/g/min, SD=0.81, range between 0.62-5.21 ml/g/min, and median=2.65 ml/g/min. With residual activity subtraction the peak stress blood flow mean=2.62 ml/g/min, SD=0.79, range=0.54-5.14 ml/g/min, and median=2.55 ml/g/min. The mean difference between individual studies was 0.12 ml/g/min with SD=0.07 or about 4%. The measures were highly correlated with linear-fit R-squared=0.99. For myocardial blood flow reserve the global mean=3.48, SD=1.15, range=0.72-8.41 and median=3.4. The residual activity subtracted metrics measured: mean=3.32, SD=1.12, range=0.62-7.98, and median=3.23. Mean difference between the measures=0.14, and SD=0.09. By linear-fit the R-squared=0.99. Conclusion: Using the prescribed low dose rest/high dose stress regadenoson N-13 ammonia PET/CT-MPI protocol, residual activity subtraction results in only a modest downward adjustment to the measured flow and reserve metrics of 4% or less. More aggressive dose reduction with N13-ammonia for the stress dose trace activity will be feasible using residual activity subtraction methodology. Acknowledgements: We would like to thank Angelina Aviles for data entry.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative Myocardial Blood Flow and Reserve with Low Dose Rest/High Dose Stress Regadenoson PET/CT-MPI: The Utility of Residual Activity Correction With N-13 Ammonia
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Quantitative Myocardial Blood Flow and Reserve with Low Dose Rest/High Dose Stress Regadenoson PET/CT-MPI: The Utility of Residual Activity Correction With N-13 Ammonia
Amy Feldkamp, Wendell Yap, Joseph Donald, Bret Press, Amy Dilberto, Michael Feldkamp, Thomas Rosamond
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 24;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Quantitative Myocardial Blood Flow and Reserve with Low Dose Rest/High Dose Stress Regadenoson PET/CT-MPI: The Utility of Residual Activity Correction With N-13 Ammonia
Amy Feldkamp, Wendell Yap, Joseph Donald, Bret Press, Amy Dilberto, Michael Feldkamp, Thomas Rosamond
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 24;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Using an assumed lung mass underestimates the lung absorbed dose in patients undergoing 90Y radioembolization therapy
  • Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
  • Usefulness of99mTc SESTAMIBI Scintigraphy in Persistent Hyperparathyroidism after Kidney Transplant
Show more Oral - PhysicianPharm

Myocardial Perfusion and Technical Advances

  • Global cardiac atherosclerotic burden assessed by fast automated artificial intelligence-based heart segmentation in 18F-sodium fluoride PET/CT scans: head-to-head comparison with manual segmentation
  • Explainable prediction of all-cause mortality from myocardial PET flow and perfusion images using deep learning
  • Improved Myocardial Blood Flow Estimation with Residual Activity and Motion Correction in 18F-flurpiridaz PET myocardial perfusion imaging
Show more Myocardial Perfusion and Technical Advances

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire